Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth

1
Type 2 Diabetes Mellitus Therapeutics in Major
Developed Markets to 2021 - Strong Pipeline and
Expanding Treatment Population to Encourage
Robust Growth
Single User License - 4995 Site User License
- 9990 Corporate User License -
14985 Publication Date - Jul 2015 Pages -
179 To know more details, email to
debora_at_reportstack.com
2
Summary

• Type 2 Diabetes Mellitus (T2DM) is a metabolic
  disease characterized by chronic hyperglycemia
  (high blood glucose levels). Global prevalence
  has risen rapidly in the past several decades,
  particularly in line with obesity. This has been
  attributed to a range of factors, including
  economic development, increasing urbanization,
  aging populations, and changes in lifestyle
  patterns such as reduced levels of physical
  activity and consumption of higher-calorie diets.

3
Scope

• Metformin monotherapy will remain the first-line
  pharmacotherapy for T2DM.
• The emergence of several new drug classes over
  the past decade, namely the Glucagon-Like
  Peptide-1 (GLP-1) receptor agonists, Dipeptidyl
  Peptidase 4 (DPP-4) inhibitors, and
  SodiumGlucose Cotransporter 2 (SGLT-2)
  inhibitors, has led to considerable market
  growth.
• Which products lead these drug classes and what
  threats do they face from the pipeline?
• How will the continued uptake of newer drug
  classes impact established drug classes such as
  the sulfonylureas and thiazolidinediones?
• Leading insulin therapy Lantus (insulin glargine)
  recently lost patent protection in most major
  markets.

4
Key Benefits

• Understand the clinical context of the T2DM
  indication and the global burden of the disease
  by considering epidemiology, symptoms, etiology,
  pathophysiology, co-morbidities and
  complications, disease classification, disease
  prognosis, and treatment options
• Appreciate the current T2DM marketed products
  landscape, including the dominant therapeutic
  strategies, products, and companies, and
  recognize gaps within the market and areas of
  unmet need
• Identify key pipeline trends in molecule type and
  molecular target

5
If you are interested...
Contact Debora White Email
debora_at_reportstack.com Ph1-888-789-6604 http/
/www.reportstack.com